Amod Kulkarni and Girish Kotwal
Background: The incidence and prevalence of prostate cancer is very high in aged individuals above 65 in the USA and across the globe,
establishing it as a prominent aging-related disorder in men. Leuprolide acetate stands as a standard treatment for aging-related metastatic
prostate cancer, aiming to lower testosterone levels to castrate levels.
Methods: This research report presents data from a patient with metastatic prostate cancer treated with leuprolide acetate to elucidate the agent's
effectiveness and limitations in managing the metastatic prostate cancer. Additionally, curcumin, yellow spice gold from turmeric that works as an
anticancer agent via multiple mechanisms including reduction in the androgen receptors and known to reduce PSA levels, was also taken as a
supplement.
Results: Following the initial dose of Leuprolide acetate, significant reductions in testosterone and PSA levels were observed. However, castrationresistant
prostate cancer developed after the second dose. Furthermore androgen depletion due to leuprolide acetate led to a substantial decline
in hemoglobin levels, resulting in anemia.
Conclusion: Lowering testosterone levels below the normal range with leuprolide acetate for aging-related metastatic prostate cancer should
not be viewed as an optimal long-term standard of care. Curcumin therapy is reported in some studies to reduce PSA levels, but did not seem to
reduce PSA levels in the patient. Earlier surgical intervention and/or procedures like arterial embolization may offer superior protection, particularly
in castration-resistant patients, compared to androgen suppression therapy.
Share this article
Journal of Clinical Case Reports received 1345 citations as per Google Scholar report
